Logo image of VLA.PA

VALNEVA SE (VLA.PA) Stock Fundamental Analysis

EPA:VLA - Euronext Paris - Matif - FR0004056851 - Common Stock - Currency: EUR

2.642  -0.03 (-1.12%)

Fundamental Rating

3

Overall VLA gets a fundamental rating of 3 out of 10. We evaluated VLA against 72 industry peers in the Biotechnology industry. VLA has a bad profitability rating. Also its financial health evaluation is rather negative. VLA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year VLA has reported negative net income.
In the past year VLA has reported a negative cash flow from operations.
VLA had negative earnings in each of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: VLA reported negative operating cash flow in multiple years.
VLA.PA Yearly Net Income VS EBIT VS OCF VS FCFVLA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

The Return On Assets of VLA (-1.66%) is better than 78.13% of its industry peers.
VLA has a better Return On Equity (-4.64%) than 75.00% of its industry peers.
Industry RankSector Rank
ROA -1.66%
ROE -4.64%
ROIC N/A
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A
VLA.PA Yearly ROA, ROE, ROICVLA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60 -80

1.3 Margins

VLA has a Gross Margin of 38.72%. This is comparable to the rest of the industry: VLA outperforms 54.69% of its industry peers.
In the last couple of years the Gross Margin of VLA has declined.
The Profit Margin and Operating Margin are not available for VLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%
VLA.PA Yearly Profit, Operating, Gross MarginsVLA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 -60

More info and screens

3

2. Health

2.1 Basic Checks

VLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, VLA has more shares outstanding
The number of shares outstanding for VLA has been increased compared to 5 years ago.
Compared to 1 year ago, VLA has a worse debt to assets ratio.
VLA.PA Yearly Shares OutstandingVLA.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
VLA.PA Yearly Total Debt VS Total AssetsVLA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

Based on the Altman-Z score of -0.33, we must say that VLA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.33, VLA perfoms like the industry average, outperforming 46.88% of the companies in the same industry.
A Debt/Equity ratio of 1.13 is on the high side and indicates that VLA has dependencies on debt financing.
With a Debt to Equity ratio value of 1.13, VLA is not doing good in the industry: 65.63% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.13
Debt/FCF N/A
Altman-Z -0.33
ROIC/WACCN/A
WACC7.72%
VLA.PA Yearly LT Debt VS Equity VS FCFVLA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M -200M

2.3 Liquidity

VLA has a Current Ratio of 2.63. This indicates that VLA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.63, VLA perfoms like the industry average, outperforming 54.69% of the companies in the same industry.
A Quick Ratio of 2.15 indicates that VLA has no problem at all paying its short term obligations.
VLA has a Quick ratio (2.15) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.63
Quick Ratio 2.15
VLA.PA Yearly Current Assets VS Current LiabilitesVLA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 93.90% over the past year.
The Revenue for VLA has decreased by -44.52% in the past year. This is quite bad
VLA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.34% yearly.
EPS 1Y (TTM)93.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72%
Revenue 1Y (TTM)-44.52%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%20.36%

3.2 Future

The Earnings Per Share is expected to grow by 36.05% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 22.69% on average over the next years. This is a very strong growth
EPS Next Y100.62%
EPS Next 2Y17.48%
EPS Next 3Y19.5%
EPS Next 5Y36.05%
Revenue Next Year10.5%
Revenue Next 2Y10.09%
Revenue Next 3Y14.66%
Revenue Next 5Y22.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VLA.PA Yearly Revenue VS EstimatesVLA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
VLA.PA Yearly EPS VS EstimatesVLA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for VLA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VLA.PA Price Earnings VS Forward Price EarningsVLA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VLA.PA Per share dataVLA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

VLA's earnings are expected to grow with 19.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.48%
EPS Next 3Y19.5%

More info and screens

0

5. Dividend

5.1 Amount

VLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VALNEVA SE

EPA:VLA (2/4/2025, 7:00:00 PM)

2.642

-0.03 (-1.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-18 2025-02-18/amc
Inst Owners25.93%
Inst Owner ChangeN/A
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap214.53M
Analysts83.08
Price Target7.77 (194.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.36%
Min EPS beat(2)-44.01%
Max EPS beat(2)72.74%
EPS beat(4)1
Avg EPS beat(4)-7.87%
Min EPS beat(4)-44.01%
Max EPS beat(4)72.74%
EPS beat(8)3
Avg EPS beat(8)-42.29%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-13.98%
Min Revenue beat(2)-14.39%
Max Revenue beat(2)-13.58%
Revenue beat(4)1
Avg Revenue beat(4)-7.48%
Min Revenue beat(4)-14.39%
Max Revenue beat(4)3.98%
Revenue beat(8)4
Avg Revenue beat(8)24.4%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.15%
PT rev (3m)-8.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)122.06%
EPS NY rev (3m)122.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.29%
Revenue NY rev (3m)0.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.97
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.51
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-2.65
FCFYN/A
OCF(TTM)-2.51
OCFYN/A
SpS2.73
BVpS2.05
TBVpS1.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.66%
ROE -4.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.72%
FCFM N/A
ROA(3y)-18.03%
ROA(5y)-13.82%
ROE(3y)-62.44%
ROE(5y)-54.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-15.75%
GM growth 5Y-10.74%
F-Score1
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 1.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.11%
Cap/Sales 5.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.63
Quick Ratio 2.15
Altman-Z -0.33
F-Score1
WACC7.72%
ROIC/WACCN/A
Cap/Depr(3y)291.07%
Cap/Depr(5y)239.89%
Cap/Sales(3y)14.73%
Cap/Sales(5y)14.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72%
EPS Next Y100.62%
EPS Next 2Y17.48%
EPS Next 3Y19.5%
EPS Next 5Y36.05%
Revenue 1Y (TTM)-44.52%
Revenue growth 3Y11.69%
Revenue growth 5Y6.34%
Sales Q2Q%20.36%
Revenue Next Year10.5%
Revenue Next 2Y10.09%
Revenue Next 3Y14.66%
Revenue Next 5Y22.69%
EBIT growth 1Y-157.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year160.39%
EBIT Next 3Y30.6%
EBIT Next 5Y25.83%
FCF growth 1Y-21.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.33%
OCF growth 3YN/A
OCF growth 5YN/A